Key Highlights

  • Third-quarter 2026 Revenue was USD 9.7 million, up 3% from USD 9.5 million.
  • Gross Margin was 75%, and total operating expenses were USD 8.5 million.
  • Net loss was USD 1.8 million, or USD 0.58 per share.
  • Cash, cash equivalents and restricted cash were approximately USD 5.7 million.

CytoSorbents (NASDAQ:CTSO) reported revenue of USD 9.7 million for the third quarter ended September 30, 2026, against an estimate of USD 9.9 million and USD 9.5 million in the third quarter of 2025. Net loss was USD 1.8 million, or USD 0.58 per share, against USD 3.2 million, or USD 1.01 per share, a year earlier, with all per-share amounts reflecting a 1-for-20 Reverse Stock Split effected on September 8, 2026. The company said it achieved Operating Cash Flow breakeven in the quarter.

Quarterly Financial Results

The company said growth was led by a 16% increase in distributor and strategic partner sales. Gross margin was 75%, against 73% in the second quarter of 2026 and 70% a year ago. Total operating expenses were USD 8.5 million, against USD 9.5 million, and excluding USD 0.25 million of restructuring charges they decreased 13%. Operating loss was USD 1.2 million, against USD 2.9 million.

Adjusted net loss, which excludes non-cash foreign currency changes, non-cash Stock Compensation and restructuring charges, was USD 1.5 million, or USD 0.48 per share, against USD 2.6 million, or USD 0.83 per share. Adjusted EBITDA loss was USD 0.3 million, against USD 2.0 million.

The company generated positive operating cash flow of approximately USD 43,000 in the quarter, excluding approximately USD 251,000 of restructuring-related payments. Total cash burn including those payments was approximately USD 200,000. Cash, cash equivalents and restricted cash were approximately USD 5.7 million on September 30, 2026, against USD 5.9 million on June 30, 2026.

Nine-Month Results and Balance Sheet

For the nine months ended September 30, 2026, revenue was USD 28.2 million, against USD 27.8 million, and gross margin was 73%, against 71%. Total operating expenses were USD 27.4 million, down 9%, and operating loss was USD 6.9 million, against USD 10.4 million. Net loss was USD 11.4 million, or USD 3.62 per share, against USD 2.7 million, or USD 0.87 per share, which the company attributed primarily to a USD 1.9 million non-cash foreign currency loss in 2026 against a USD 9.1 million non-cash foreign currency gain in 2025. Adjusted EBITDA loss was USD 4.0 million, against USD 7.3 million.

Cash and cash equivalents were USD 4.2 million, against USD 6.2 million at year-end 2025, with restricted cash of USD 1.5 million. Inventories were USD 3.2 million, against USD 5.3 million, and Accounts Receivable were USD 7.1 million, against USD 7.6 million. Total Assets were USD 37.2 million, against USD 44.2 million.

Commercial and Regulatory Update

Distributor and strategic partner sales grew 18% year over year and 10% sequentially, and direct sales outside Germany increased 4%, together accounting for 76% of quarterly sales. Sales in Germany declined 20% year over year and represented 24% of quarterly sales, which the company attributed primarily to a smaller sales force and reduced territory coverage following commercial restructuring. It reported a 24% reduction in headcount since September 2025 and the appointment of Alex Tiefenbacher as Senior Vice President of Direct Sales.

For DrugSorb-ATR, the company cited an independent patient-matched analysis of 587 patients undergoing urgent coronary artery bypass grafting after recent ticagrelor exposure, presented at the European Society of Cardiology congress in August. The analysis reported severe BARC-4 bleeding of 21.8% with intraoperative CytoSorb use against 34.5% for control, with a p-value of 0.002. The company plans a new De Novo submission to the FDA in early 2027 and a separate De Novo submission next year for direct oral anticoagulants.

For HemoDefend-BGA, developed with approximately USD 16 million in prior non-dilutive U.S. government funding, the company said it is evaluating government funding, commercial partnerships and licensing arrangements following FDA feedback in July.